For cT3b N1 rectal cancer with positive left-sided pelvic lymph nodes, is the recommended treatment surgery, radiotherapy, or neoadjuvant chemoradiotherapy followed by surgery?

Treatment for cT3bN1 Rectal Cancer with Positive Left-Sided Pelvic Lymph Nodes

For cT3bN1 rectal cancer with positive left-sided pelvic lymph nodes, the standard treatment is neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME) surgery, not surgery or radiotherapy alone. 1

Standard Treatment Approach: Total Neoadjuvant Therapy (TNT)

The optimal treatment sequence is long-course chemoradiotherapy (50.4 Gy with concurrent fluoropyrimidine) followed by consolidation chemotherapy (FOLFOX or CAPOX for 3-4 cycles), then TME surgery 6-8 weeks after completing all neoadjuvant treatment. 1, 2

Why This Approach is Superior

• External radiotherapy followed by surgery is the established standard for T3 or node-positive rectal cancer, as it reduces local recurrence rates from 10.1% to 7.1% compared to surgery alone. 1
• Preoperative therapy is strongly preferred over postoperative treatment because it is more effective (better local control) and less toxic (27% vs 40% grade 3+ toxicity). 1
• TNT achieves higher chemotherapy completion rates (≈90% vs 50-60% with adjuvant therapy) and greater pathologic complete response rates (22-25% vs 14-15% with chemoradiotherapy alone). 2

Specific Treatment Components

Neoadjuvant Chemoradiotherapy Regimen

• Deliver 45.0-50.4 Gy over 25-28 fractions (1.8-2.0 Gy per fraction) to the pelvis. 1
• The radiation field must include the tumor with 2-5 cm safety margin, presacral lymph nodes, internal iliac lymph nodes, and obturator lymph nodes. 1
• For left-sided pelvic nodes specifically, external iliac lymph nodes should be included in the radiation field when T3 tumors demonstrate lateral extension. 1
• Concurrent chemotherapy should be continuous-infusion 5-FU (225 mg/m²/day) or oral capecitabine (825 mg/m² twice daily, 5 days per week). 1

Consolidation Chemotherapy

• After completing chemoradiotherapy, administer 3-4 cycles of FOLFOX or CAPOX before surgery. 2, 3
• This consolidation approach is superior to induction chemotherapy given before radiation (25% vs 17% pathologic complete response). 2

Surgical Management

• Perform TME surgery 6-8 weeks after completing all neoadjuvant treatment to allow maximal tumor regression. 1, 2
• The surgery must achieve negative circumferential resection margins (≥1 mm clearance) and examine at least 12 regional lymph nodes. 1

Management of Lateral Pelvic Lymph Nodes

For confirmed left-sided pelvic lymph node metastasis on imaging, neoadjuvant chemoradiotherapy is recommended first, followed by reassessment. 1, 4

• If the lymph node disappears on post-treatment imaging, follow-up observation may be conducted without lateral lymph node dissection. 1
• If LPLNs demonstrate pretreatment heterogeneity and irregular margin, or remain ≥5 mm short-axis post-TNT, lateral pelvic lymph node dissection should be considered at the time of TME. 4
• Prophylactic dissection of lateral lymph nodes without confirmed imaging diagnosis is not recommended. 1

Post-Surgical Adjuvant Therapy

• Complete a total of 6 months of systemic chemotherapy (including the pre-operative consolidation phase). 1, 2
• Postoperative adjuvant treatment should start as early as possible and no later than 8 weeks after surgery. 2

Critical Pitfalls to Avoid

• Do not perform surgery alone without neoadjuvant therapy for T3N1 disease, as this results in significantly higher local recurrence rates. 1
• Do not use short-course radiotherapy (5×5 Gy) for this presentation, as it yields inferior local control compared to long-course chemoradiotherapy (10% vs 6% locoregional recurrence at 5 years). 1, 2
• Do not add oxaliplatin, bevacizumab, or cetuximab to concurrent chemoradiotherapy, as these agents increase toxicity without survival benefit and may worsen surgical complications. 2, 3
• Do not delay surgery beyond 8-10 weeks after completing TNT, as this may permit tumor regrowth. 2
• Approximately 22% of clinically staged T3N0 patients harbor occult nodal metastases, supporting the use of neoadjuvant therapy even when nodes appear negative on imaging. 2